Protein Chemistry Laboratory, Department of Biology, College of Sciences, Shiraz University, Iran.
Appl Biochem Biotechnol. 2012 Jun;167(4):861-72. doi: 10.1007/s12010-012-9733-5. Epub 2012 May 24.
The development of resistance and unwanted harmful interaction with other biomolecules instead of DNA are the major drawbacks for application of platinum (Pt) complexes in cancer chemotherapy. To conquer these problems, much works have been done so far to discover innovative Pt complexes. The objective of the current study was to evaluate the anti cancer activities of a series of four and five-coordinated Pt(II) complexes, having deprotonated 2-phenyl pyridine (abbreviated as C^N), biphosphine moieties, i.e., dppm = bis(diphenylphosphino) methane (Ph(2)PCH(2)PPh(2)) and dppa = bis(diphenylphosphino)amine (Ph(2)PNHPPh(2)), as the non-leaving carrier groups. The growth inhibitory effect of the Pt complexes [Pt(C^N)(dppm)]PF(6): C(1), [Pt(C^N)(dppa)]PF(6): C(2), and [Pt(C^N)I(dppa)]: C(3), toward the cancer cell lines was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. In addition, the florescence quenching experiments of the interaction between human serum albumin (HSA) and the Pt complexes were performed in order to obtain the binding parameters and to evaluate the denaturing properties of these complexes upon binding to the general carrier protein of blood stream. The structure-activity relationship studies reveal that four-coordinated Pt complexes C(1) and C(2) with both significant hydrophobic and charge characteristics, not only exhibit strong antiproliferation activity toward the cancer cell lines, but also they display lower denaturing effect against carrier protein HSA. On the other hand, five-coordinated C(3) complex with the unusual intermolecular NH…Pt hydrogen binding and the intrinsic ability for oligomerization, exhibits poor anticancer activity and strong denaturing property. The current study reveals that the balance between charge and hydrophobicity of the Pt complexes, also their hydrogen binding abilities and coordination mode are important for their anticancer activities. Moreover, this study may suggest C(1) and C(2) as the potential template structures for synthesis of new generation of four-coordinated Pt complexes with strong anticancer activities and weak denaturing effects against proteins.
铂(Pt)配合物在癌症化疗中的应用主要存在两个缺点:耐药性的发展和与其他生物分子的不良有害相互作用,而不是 DNA。为了解决这些问题,目前已经做了大量工作来发现创新的 Pt 配合物。本研究的目的是评估一系列四配位和五配位 Pt(II)配合物的抗癌活性,这些配合物具有去质子化的 2-苯基吡啶(简称 C^N)和双膦配体,即 dppm = 双(二苯基膦基)甲烷(Ph(2)PCH(2)PPh(2))和 dppa = 双(二苯基膦基)胺(Ph(2)PNHPPh(2)),作为非离去载体基团。使用 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴化物测定法测量 Pt 配合物[Pt(C^N)(dppm)]PF(6):C(1)、[Pt(C^N)(dppa)]PF(6):C(2)和[Pt(C^N)I(dppa)]:C(3)对癌细胞系的生长抑制作用。此外,还进行了人血清白蛋白(HSA)与 Pt 配合物相互作用的荧光猝灭实验,以获得结合参数,并评估这些配合物与血流中通用载体蛋白结合时的变性特性。结构-活性关系研究表明,具有显著疏水性和电荷特性的四配位 Pt 配合物 C(1)和 C(2)不仅对癌细胞系表现出很强的增殖抑制活性,而且对载体蛋白 HSA 的变性作用也较小。另一方面,具有异常分子间 NH…Pt 氢键和内在聚合能力的五配位 C(3)配合物表现出较差的抗癌活性和较强的变性特性。本研究表明,Pt 配合物的电荷和疏水性之间的平衡,以及它们的氢键能力和配位方式对其抗癌活性很重要。此外,这项研究可能表明 C(1)和 C(2)作为新一代具有强抗癌活性和弱蛋白变性作用的四配位 Pt 配合物的潜在模板结构。